Elamipretide
ALSO SOLD AS SS-31
Last reviewed 2026-10-30
Our read Opinion
Now an FDA-approved rare-disease medicine, not simply an unapproved research peptide. Approval rests on an intermediate muscle-strength endpoint; broad anti-aging benefits are not established.
- Type
- FDA-approved
- Regulatory status
- FDA accelerated approval (Forzinity, 2025)
- Compounding status
- Approved product (not applicable)
- FDA-approved indications
- Improvement of muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg (accelerated approval).
- Evidence level
- Small/early human studies
- Routes studied
- —
- WADA
- Verify
- Developer
- Stealth BioTherapeutics
Claims made by researchers, companies and users. Inclusion does not mean the claim is verified.
- —Claimed to support cellular energy and endurance
Mitochondria-targeting tetrapeptide that binds cardiolipin in the inner mitochondrial membrane to support mitochondrial structure and function.
FDA granted Forzinity accelerated approval on September 19, 2025, to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg. Continued approval may depend on confirmatory evidence of clinical benefit.
Statuses change; check the linked primary source.
Momentum Opinion
Watch
0 news items in last 30 days
The Barth syndrome approval is important but should not be generalized to wellness or longevity. The small evidence base and confirmatory requirement warrant unusually careful framing.
No news yet for this peptide.
Better cellular energy, endurance and 'mitochondrial aging' support.
Information only. Not medical advice. Listing a compound is not an endorsement or a recommendation to obtain or use it. Ratings and "Our Take" are editorial opinion. Full disclaimer.